Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered question first ministerially corrected answering member label previous answer version answering member constituency answering member printed answering member
tabling member	label

Search

61553

	registered interest
	date	12/06/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Learning Disability: Health Services
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have to ensure that people with learning disabilities are not excluded from NHS England's five-year strategic plan for National Health Service commissioners to improve quality of and access to health care, outlined in Everyone Counts: Planning for Patients 2014/15–2018/19.
	tabling member printed	Baroness Hollins
	uin	HL322
	answer	answer is ministerial correction date of answer 26/06/2014 answer text <p>The Government's Mandate to NHS England, sets out our ambitions for the health service, which include an objective that NHS England ensures clinical commissioning groups work with local authorities to ensure that vulnerable people, particularly those with learning disabilities and autism, receive safe, appropriate, high quality care. NHS England sets out how it will achieve the objectives in the Mandate in its 2014-15 – 2016-17 business plan. The Government will hold NHS England to account for its achievement.</p><p> </p><p><em>Everyone Counts: Planning for Patients 2014/15 to 2018/19</em>sets out a framework within which commissioners will need to work with providers and partners in local government to develop five year plans to secure the continuity of sustainable high quality care for all. Building on <em>Everyone Counts</em>, NHS England is beginning a programme of work to consider how to improve quality of and access to health care for people with learning disabilities. Within the framework there is specific reference to <em>Transforming Care: A national response to Winterbourne View Hospital. </em>This is a non-negotiable item that NHS England expects to be part of every relationship between commissioners and providers. As part of this, clinical commissioning groups, local authorities and specialised commissioners should work together to implement the core specification which describes the core principles that must be present in all education, health and social care services for children, young people, adults and older people with learning disabilities and/or autism who either display, or are at risk of displaying, behaviour that challenges.</p><p> </p><p>NHS England is committed to work to reduce premature mortality amongst people with learning disability, including actions in response to the Confidential Inquiry into Premature Deaths of People with Learning Disabilities.</p><p> </p> answering member printed Earl Howe question first answered 26/06/2014 14:01:36 question first ministerially corrected 26/06/2014 15:34:49 answering member 2000 label Biography information for Earl Howe previous answer version 6304 answering member printed Earl Baldwin of Bewdley answering member 3446
	tabling member	4190 label Biography information for Baroness Hollins

169515

	registered interest
	date	10/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Health Professions: Regulation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what amount each of the healthcare regulators charged for annual registration fees in each of the last five years.
	tabling member constituency	Copeland
	tabling member printed	Mr Jamie Reed
	uin	218058
	answer	answer is ministerial correction date of answer 15/12/2014 answer text <p>The regulatory bodies are independent and it is therefore for them to set their fees appropriately. All professional regulators, are aware of the Governments position, as set out in the 2011 Command Paper, `Enabling Excellence’, that we would not expect registration fees to increase, unless there is a clear and strong case that any increase is essential to ensure the exercise of statutory duties.</p><p> </p><p>There are eight Healthcare Professions Regulatory Bodies (excluding the Pharmaceutical Society in Northern Ireland where responsibility is devolved to the Northern Ireland Assembly). The Department does not hold information on the fees of the regulatory bodies. However, we have obtained data from each of the regulatory bodies on the Annual Retention Fee for the last five years which shows:</p><p> </p><p> </p><p>Annual Retention Fee for Healthcare Professions Regulatory Bodies 2010-2015</p><p> </p><table><tbody><tr><td><p>Year</p></td><td><p>Nursing and Midwifery Council</p></td><td><p>Health and Care Professions Council</p></td><td><p>General Optical Council</p></td><td><p>General Medical Council</p></td><td><p>General Osteopathic Council</p></td><td><p>General Pharmaceutical Council</p></td><td><p>General Dental Council</p></td><td><p>General Chiropractic Council</p></td></tr><tr><td><p>2014-15</p></td><td><p>£100</p></td><td><p>£80</p></td><td><p>£290</p></td><td><p>£390</p></td><td><p>£570</p></td><td><p>£240</p></td><td><p>£576</p></td><td><p>£800</p></td></tr><tr><td><p>2013-14</p></td><td><p>£100</p></td><td><p>£76</p></td><td><p>£260</p></td><td><p>£390</p></td><td><p>£610</p></td><td><p>£240</p></td><td><p>£576</p></td><td><p>£800</p></td></tr><tr><td><p>2012-13</p></td><td><p>£76</p></td><td><p>£76</p></td><td><p>£260</p></td><td><p>£390</p></td><td><p>£655</p></td><td><p>£240</p></td><td><p>£576</p></td><td><p>£800</p></td></tr><tr><td><p>2011-12</p></td><td><p>£76</p></td><td><p>£76</p></td><td><p>£270</p></td><td><p>£390</p></td><td><p>£750</p></td><td><p>£267</p></td><td><p>£576</p></td><td><p>£800</p></td></tr><tr><td><p>2010 -11</p></td><td><p>£76</p></td><td><p>£76</p></td><td><p>£280 (Dispensing optician)</p><p>£325 (Optometrist)</p></td><td><p>£420</p></td><td><p>£750</p></td><td><p>£262</p></td><td><p>£438</p></td><td><p>£1,000</p></td></tr></tbody></table><p> </p><p> </p><p>The Department does not hold data on the number of investigations that have been carried out by each of the healthcare professions regulatory bodies. We understand that this information is published by each of the regulatory bodies.</p><p> </p><p>The Department has five national bodies which have regulatory functions. They are the Care Quality Commission, Monitor, the Human Fertilisation and Embryology Authority, the Human Tissue Authority and the Medicines and Healthcare products Regulatory Agency. None of these bodies charge an annual registration fee but <ins class="ministerial">all except Monitor </ins><del class="ministerial">they do</del> receive income from a range of fees that are applied.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 15/12/2014 17:43:27 question first ministerially corrected 18/12/2014 14:09:00 answering member 3932 label Biography information for Dr Dan Poulter previous answer version 33732 answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter answering member 3932 label Biography information for Dr Dan Poulter
	tabling member	1503 label Biography information for Mr Jamie Reed

168664

	registered interest
	date	08/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Abortion
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many abortions were refused on the grounds on coercion in the last year for which records are available.
	tabling member constituency	Fylde
	tabling member printed	Mark Menzies
	uin	217766
	answer	answer is ministerial correction date of answer 15/12/2014 answer text <p>The Department does <ins class="ministerial">not </ins>hold this information.</p><p> </p><p> </p><p> </p><p>We take the issue of coercion seriously and staff working in abortion clinics are experienced and highly skilled in discussing sensitive issues with women and identifying whether there is any coercion or other risks to the woman.</p><p> </p><p> </p><p> </p><p>Women who present for an abortion will always have the opportunity to speak to a health professional on their own at some point during the consultation. Pathways should be in place to refer women to specialised services if coercion is identified.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 15/12/2014 16:55:05 question first ministerially corrected 15/12/2014 17:10:17 answering member 3918 label Biography information for Jane Ellison previous answer version 33589 answering member constituency Battersea answering member printed Jane Ellison answering member 3918 label Biography information for Jane Ellison
	tabling member	3998 label Biography information for Mark Menzies

168663

	registered interest
	date	08/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Abortion
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many women were referred onwards to other care pathways after it was determined that they were being coerced into seeking an abortion in the last year for which records are available.
	tabling member constituency	Calder Valley
	tabling member printed	Craig Whittaker
	uin	217763
	answer	answer is ministerial correction date of answer 15/12/2014 answer text <p>The Department does <ins class="ministerial">not </ins>hold this information.</p><p> </p><p> </p><p> </p><p>We take the issue of coercion seriously and staff working in abortion clinics are experienced and highly skilled in discussing sensitive issues with women and identifying whether there is any coercion or other risks to the woman.</p><p> </p><p> </p><p> </p><p>Women who present for an abortion will always have the opportunity to speak to a health professional on their own at some point during the consultation. Pathways should be in place to refer women to specialised services if coercion is identified.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 15/12/2014 16:55:05 question first ministerially corrected 15/12/2014 17:10:17 answering member 3918 label Biography information for Jane Ellison previous answer version 33588 answering member constituency Battersea answering member printed Jane Ellison answering member 3918 label Biography information for Jane Ellison
	tabling member	3940 label Biography information for Craig Whittaker

167082

	registered interest
	date	01/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Sickle Cell Diseases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what estimate he has made of the annual cost to the NHS of treating sickle cell anaemia.
	tabling member constituency	Wolverhampton South East
	tabling member printed	Mr Pat McFadden
	uin	216529
	answer	answer is ministerial correction date of answer 08/12/2014 answer text <p>There are an estimated 250,000 people with <ins class="ministerial">the</ins> sickle cell <ins class="ministerial">trait</ins> <del class="ministerial">anaemia</del> in the United Kingdom. The Department has made no estimation of the annual cost of treating sickle cell anaemia in the National Health Service nor does it hold information on the total NHS spend on sickle cell anaemia.</p><p> </p><p> </p><p> </p><p>The Department does hold estimated costs for admitted patient care episodes as reported by Healthcare Resource Groups. In 2013-14 the total estimated figure for sickle anaemia was £23.8 million; in 2012-13 it was £21.9 million. This figure does not include other costs such as primary and social care.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 08/12/2014 15:12:22 question first ministerially corrected 10/12/2014 16:29:44 answering member 3918 label Biography information for Jane Ellison previous answer version 32239 answering member constituency Battersea answering member printed Jane Ellison answering member 3918 label Biography information for Jane Ellison
	tabling member	1587 label Biography information for Pat McFadden

167080

	registered interest
	date	01/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Sickle Cell Diseases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much the NHS spends on sickle cell anaemia; and what proportion this is of the total NHS budget.
	tabling member constituency	Wolverhampton South East
	tabling member printed	Mr Pat McFadden
	uin	216527
	answer	answer is ministerial correction date of answer 08/12/2014 answer text <p>There are an estimated 250,000 people with <ins class="ministerial">the</ins> sickle cell <ins class="ministerial">trait</ins> <del class="ministerial">anaemia</del> in the United Kingdom. The Department has made no estimation of the annual cost of treating sickle cell anaemia in the National Health Service nor does it hold information on the total NHS spend on sickle cell anaemia.</p><p> </p><p> </p><p> </p><p>The Department does hold estimated costs for admitted patient care episodes as reported by Healthcare Resource Groups. In 2013-14 the total estimated figure for sickle anaemia was £23.8 million; in 2012-13 it was £21.9 million. This figure does not include other costs such as primary and social care.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 08/12/2014 15:12:22 question first ministerially corrected 10/12/2014 16:29:44 answering member 3918 label Biography information for Jane Ellison previous answer version 32239 answering member constituency Battersea answering member printed Jane Ellison answering member 3918 label Biography information for Jane Ellison
	tabling member	1587 label Biography information for Pat McFadden

105978

	registered interest
	date	03/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pay
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many Instant Rewards of what value were given to his Department's officials in (a) 2013 and (b) 2014 to date.
	tabling member constituency	Barrow and Furness
	tabling member printed	John Woodcock
	uin	213068
	answer	answer is ministerial correction date of answer 10/11/2014 answer text <p><del class="ministerial">The Civil Service Commission publish details of appointments made by exception and approved by them in their annual reports and on their website. These reports are available in the Library.</del></p><p><br /><del class="ministerial">It would not be appropriate to publish details of the requests turned down by the Commission as the numbers involved are small, and the individuals might be personally identified, directly or in combination with other published information.</del></p><p> </p><p><ins class="ministerial">The Department does not operate an ‘Instant Rewards’ scheme. The Department does, however, operate an in-year bonus scheme, which has strict criteria, approval processes and budgetary control.</ins></p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 10/11/2014 16:58:06 question first ministerially corrected 10/11/2014 17:38:55 answering member 3932 label Biography information for Dr Dan Poulter previous answer version 27280 answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter answering member 3932 label Biography information for Dr Dan Poulter
	tabling member	3917 label Biography information for Lord Walney

100887

	registered interest
	date	24/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Asthma
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much public funding was allocated to research into asthma in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	uin	211918
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:12:28 question first ministerially corrected 13/11/2014 10:22:56 answering member 4020 label Biography information for George Freeman previous answer version 25123 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	4026 label Biography information for Liz Kendall

100885

	registered interest
	date	24/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Asthma: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much the Government has spent on the development of new drugs to treat the symptoms of asthma in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	uin	211885
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:12:29 question first ministerially corrected 13/11/2014 10:22:56 answering member 4020 label Biography information for George Freeman previous answer version 25123 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	4026 label Biography information for Liz Kendall

100730

	registered interest
	date	23/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Osteoporosis: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much from the public purse has been spent on the development of new drugs to treat symptoms of osteoporosis in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	uin	211735
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:12:28 question first ministerially corrected 13/11/2014 10:22:56 answering member 4020 label Biography information for George Freeman previous answer version 25123 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	4026 label Biography information for Liz Kendall